RVTY · News · 20260804N

Revenue Performance and Mix

REVVITY, INC. · 2026-08-04 · Importance 25 · Surprise 32

Revvity reported second-quarter 2026 revenue of $729.69 million, up from $720.28 million a year earlier, representing approximately 1.3% YoY growth. The Diagnostics segment delivered 11% organic growth and offset a decline in the Life Sciences segment. Demand increased for drug-development tools, diagnostic testing products, and high-content screening orders, while software revenue remained volatile.

Key facts

• Q2 CY2026 revenue increased 7.2% year-on-year to $729.7 million. source
• Q2 2026 revenue: $730 million. source
• Q2 2026 revenues: $729.69 million. source
• Diagnostics segment organic growth in Q2 2026: 11%. source